Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Public Safety topic
No spam. Unsubscribe anytime.
Committee advances two public‑safety bills: jail standards supervision moved and crime lab can share toxicology with drug director
Summary
Lawmakers approved changes to agency supervision of a jail standards officer and added the state drug director as an authorized recipient of crime‑lab toxicology reports to help track overdose patterns across jurisdictions.
Two related bills concerning public safety and criminal forensic data were presented together and advanced by the committee.
House Bill 18‑42 (as described in committee) relocates the jail inspection/standards officer’s administrative oversight from a generic assignment within the Department of Public Safety to the Commission on Law Enforcement Standards, clarifying who supervises and evaluates that officer. Secretary Mike Hager told the committee the change affects one position and does not change pay or create a budgetary impact.
House Bill 18‑43 would add the state drug director to the statutory list of authorized recipients of toxicology reports from the state crime lab. Secretay Hager said that the drug director — currently operating under a memorandum of understanding with DPS while assigned to the Department of Human Services — has built a database and mapping capability to plot overdose cases that cross jurisdictional lines. The director’s access to toxicology would allow the office to identify patterns and “hot spots” where illicit suppliers may be operating across county and city boundaries.
Several senators pressed privacy and confidentiality questions: committee members asked whether the drug director is a law‑enforcement official, how confidentiality and FOIA exceptions would apply, and whether sharing data would interfere with prosecution or ongoing investigations. Hager said the crime lab records are privileged and confidential under statute and that access would still be limited to appropriate investigative and prosecutorial channels; he said the drug director in office has prior law‑enforcement experience and that the arrangement is supported by an MOU.
Both bills were advanced on committee voice votes with no recorded roll call.
Why it matters: Supporters said adding the drug director to the list of recipients will improve interjurisdictional drug enforcement and allow faster, targeted responses to overdose patterns. Questions remain about administrative authority, confidentiality rules and how the drug director’s access will be operationalized within statutory privacy protections.
Next steps: Both bills advance to the full Senate; committee direction included confirming confidentiality protections and how the drug director would handle privileged crime‑lab data.
